Researchers at Australia’s Garvan Institute of Medical Research have identified a previously under-recognised immune-cell problem in mevalonate kinase deficiency (MKD), a rare inherited disorder that can cause recurring episodes of fever and severe inflammation. The study reports that natural killer cells — immune cells that normally help destroy infected or abnormal cells — fail to mature and function properly in people with the condition. The finding challenges a long-standing explanation that focused mainly on another immune-cell type, macrophages. The research, published in Immunity, identifies natural killer cell dysfunction and interferon-gamma signalling as central features of the disease.

According to the researchers, affected natural killer cells can struggle to release the toxic granules they use to destroy target cells. Instead, they produce excessive amounts of interferon gamma, a powerful immune signal that can intensify inflammation. The team used patient samples and preclinical models to investigate how this process contributes to disease symptoms. The findings may help explain why existing treatments do not adequately control inflammation in every patient. Garvan’s institutional report describes the cellular mechanism and the research collaboration.

The study also describes an early treatment observation involving baricitinib, a JAK-inhibiting medicine, added to the treatment regimen of a severely affected infant. Doctors reported improvement, but a single patient’s response cannot establish effectiveness or safety for the wider MKD population. Larger clinical studies will be needed before this approach can be recommended as a standard treatment. The research may also guide investigations into related inherited inflammatory disorders. The Immunity paper provides the scientific basis and should be consulted for clinical interpretation.
